GreenLight SPAC Presentation Deck

CBH mRNA Influenza vaccines in development Success of COVID-19 RNA vaccines has renewed interest in influenza Company GreenLight BIOSCIENCES™ BIONTECH Pfizer moderna UREVAC the RNA people Translate BIO gsk SANOFI PASTEUR ARCTURUS therapeutics Agent Name GLB-flu-xx BNT-161 mRNA-1010 mRNA-1020 mRNA-1030 mRNA-1440 CV7301 Undisclosed Undisclosed LUNAR-FLU Description Seasonal influenza Seasonal influenza Seasonal influenza Seasonal influenza Seasonal influenza Avian influenza virus Seasonal influenza Universal influenza with Gates Funding Undisclosed Seasonal influenza Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Stage of Development Preclinical Phase 1 projected to begin 2H 2022 Preclinical Phase 1 to begin 2H 2021 Phase 1 to begin in 2021 Phase 1 to begin in 2021 Phase 1 to begin in 2021 Positive Ph1 reported in 2017 Preclinical Preclinical IND enabling Phase 1 to begin in 2021 Preclinical IND filing expected 1H 2022 HUMAN HEALTH 26

View entire presentation